- Home
- SCSC vs AUTL Comparison
SCSC vs AUTL Comparison
Compare SCSC & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCSC
- AUTL
- Stock Information
- Founded
- SCSC 1992
- AUTL 2014
- Country
- SCSC United States
- AUTL United Kingdom
- Employees
- SCSC N/A
- AUTL N/A
- Industry
- SCSC Retail: Computer Software & Peripheral Equipment
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SCSC Technology
- AUTL Health Care
- Exchange
- SCSC Nasdaq
- AUTL Nasdaq
- Market Cap
- SCSC 1.2B
- AUTL 1.1B
- IPO Year
- SCSC 1994
- AUTL 2018
- Fundamental
- Price
- SCSC $49.72
- AUTL $4.70
- Analyst Decision
- SCSC Hold
- AUTL Strong Buy
- Analyst Count
- SCSC 2
- AUTL 2
- Target Price
- SCSC $36.00
- AUTL $9.50
- AVG Volume (30 Days)
- SCSC 218.8K
- AUTL 715.4K
- Earning Date
- SCSC 11-07-2024
- AUTL 10-31-2024
- Dividend Yield
- SCSC N/A
- AUTL N/A
- EPS Growth
- SCSC N/A
- AUTL N/A
- EPS
- SCSC 3.06
- AUTL N/A
- Revenue
- SCSC $3,259,809,000.00
- AUTL $10,497,000.00
- Revenue This Year
- SCSC $3.41
- AUTL $816.67
- Revenue Next Year
- SCSC $5.25
- AUTL $374.47
- P/E Ratio
- SCSC $16.12
- AUTL N/A
- Revenue Growth
- SCSC N/A
- AUTL 40.22
- 52 Week Low
- SCSC $27.86
- AUTL $2.21
- 52 Week High
- SCSC $53.29
- AUTL $7.45
- Technical
- Relative Strength Index (RSI)
- SCSC 60.98
- AUTL 72.40
- Support Level
- SCSC $47.23
- AUTL $3.92
- Resistance Level
- SCSC $48.78
- AUTL $4.38
- Average True Range (ATR)
- SCSC 1.25
- AUTL 0.22
- MACD
- SCSC 0.25
- AUTL 0.09
- Stochastic Oscillator
- SCSC 95.56
- AUTL 88.64
About SCSC ScanSource Inc.
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Modern Communications and Cloud. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the Company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.